论文部分内容阅读
1.前言 2008年6月,来自中国、美国、欧洲的急诊科、心血管科、实验室及内科临床专家相聚在中国上海。他们计划: 1.比较中国与欧美的心力衰竭监护标准、评估及预后标准。 2.回顾心力衰竭中利钠肽(BNP)的应用,特别在下述方面: (1)BNP在呼吸困难患者中的应用;(2)BNP在医院中的应用; (3)BNP在门诊患者中的应用;(4)BNP的“灰值”区间;(5)BNP在心衰及肾功能障碍中的应用;(6)BNP及最新指南。 3.最终,临床医师们将在讨论后发布第一个中西方BNP专家共识。
1. Introduction In June 2008, emergency department, cardiovascular department, laboratory and medical clinical experts from China, the United States and Europe gathered in Shanghai, China. They plan: 1. Compare Chinese and European heart failure guardianship standards, assessment and prognostic criteria. 2. Review the use of natriuretic peptide (BNP) in heart failure, in particular in the following areas: (1) the use of BNP in patients with dyspnea; (2) the use of BNP in hospitals; (3) the use of BNP in outpatients (4) BNP “gray value ” interval; (5) BNP in heart failure and renal dysfunction; (6) BNP and the latest guidelines. 3. Finally, clinicians will release the first BNP-BNP consensus after discussions.